Iatrogenic Cost Factors Incorporating Mild and Moderate Adverse Events in the Economic Comparison of Aceclofenac and Other NSAIDs
- 1 January 2001
- journal article
- research article
- Published by Springer Nature in PharmacoEconomics
- Vol. 19 (7) , 779-790
- https://doi.org/10.2165/00019053-200119070-00006
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Probabilistic Sensitivity Analysis Incorporating the BootstrapMedical Decision Making, 1999
- Measuring the Effects of Medication Use on Health-Related Quality of Life in Patients with Rheumatoid ArthritisPharmacoEconomics, 1999
- Choice of NSAID and Management Strategy in Rheumatoid Arthritis and OsteoarthritisPharmacoEconomics, 1998
- The Use of Consensus Methods and Expert Panels in Pharmacoeconomic StudiesPharmacoEconomics, 1997
- THE COST OF RHEUMATOID ARTHRITISRheumatology, 1996
- Comparison of aceclofenac with diclofenac in the treatment of osteoarthritisClinical Rheumatology, 1995
- The iatrogenic cost of non-steroidal anti-inflammatory drug therapyRheumatology, 1995
- Aceclofenac versus naproxen in the treatment of ankylosing spondylitis: A double-blind, controlled studyCurrent Therapeutic Research, 1994
- Pharmacoeconomics of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)PharmacoEconomics, 1993
- The Economic Consequences of NSAID-Induced Gastropathy: The French ContextScandinavian Journal of Rheumatology, 1992